News on Xeloda from BioPortfolio.com http://www.BioPortfolio.com Consolidated Xeloda news from BioPortfolio.com Tue, 09 Feb 2010 22:49:23 GMT en Roche expands Herceptin franchisehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032067&HITNO=0&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032067&THISHREF=http://c.moreover.com/click/here.pl%3fz2534493361%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032067&HITNO=0&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032067&THISHREF=http://c.moreover.com/click/here.pl%3fz2534493361%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmafocus: Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-040http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4025325&HITNO=1&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4025325&THISHREF=http://c.moreover.com/click/here.pl%3fz2529669943%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4025325&HITNO=1&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4025325&THISHREF=http://c.moreover.com/click/here.pl%3fz2529669943%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaceuticalProcessing: FDA Expands Use of Approved Breast Cancer Drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4025136&HITNO=2&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4025136&THISHREF=http://c.moreover.com/click/here.pl%3fz2529450489%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4025136&HITNO=2&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4025136&THISHREF=http://c.moreover.com/click/here.pl%3fz2529450489%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Strong operating performance for Roche in 2009http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023958&HITNO=3&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023958&THISHREF=http://c.moreover.com/click/here.pl%3fz2528518445%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023958&HITNO=3&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023958&THISHREF=http://c.moreover.com/click/here.pl%3fz2528518445%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comWorld Pharma News: FDA Okays Drug Combo for Advanced Breast Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019494&HITNO=4&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019494&THISHREF=http://c.moreover.com/click/here.pl%3fz2526322808%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019494&HITNO=4&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019494&THISHREF=http://c.moreover.com/click/here.pl%3fz2526322808%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBreastcancer.org: AEterna Zentaris says Keryx reaches SPA agreement with FDA for Phase III study of perifosinehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4015057&HITNO=5&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4015057&THISHREF=http://c.moreover.com/click/here.pl%3fz2524251758%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4015057&HITNO=5&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4015057&THISHREF=http://c.moreover.com/click/here.pl%3fz2524251758%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: AEterna Zentaris says Keryx reaches SPA agreement with FDA for Phase III study of perifosinehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014980&HITNO=6&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014980&THISHREF=http://c.moreover.com/click/here.pl%3fz2524231218%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014980&HITNO=6&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014980&THISHREF=http://c.moreover.com/click/here.pl%3fz2524231218%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Keryx Biopharmaceuticals Announces Protocol Assessment Agreement With FDA For Phase 3 Trial Of KRX-0401 (Perifhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4012630&HITNO=7&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4012630&THISHREF=http://c.moreover.com/click/here.pl%3fz2523486045%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4012630&HITNO=7&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4012630&THISHREF=http://c.moreover.com/click/here.pl%3fz2523486045%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: Keryx, FDA agree on colon cancer drug study goalshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006731&HITNO=8&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006731&THISHREF=http://c.moreover.com/click/here.pl%3fz2520845141%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006731&HITNO=8&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006731&THISHREF=http://c.moreover.com/click/here.pl%3fz2520845141%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Keryx, FDA Agree on Colon Cancer Drug Study Goalshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007303&HITNO=9&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007303&THISHREF=http://c.moreover.com/click/here.pl%3fz2521072632%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007303&HITNO=9&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007303&THISHREF=http://c.moreover.com/click/here.pl%3fz2521072632%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comABC News: Keryx, FDA agree on colon cancer drug study goalshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007184&HITNO=10&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007184&THISHREF=http://c.moreover.com/click/here.pl%3fz2521043257%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007184&HITNO=10&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007184&THISHREF=http://c.moreover.com/click/here.pl%3fz2521043257%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioscience Technology Online: Keryx, FDA agree on colon cancer drug study goalshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007183&HITNO=11&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007183&THISHREF=http://c.moreover.com/click/here.pl%3fz2521042638%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007183&HITNO=11&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007183&THISHREF=http://c.moreover.com/click/here.pl%3fz2521042638%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Malaysia: Keryx, FDA agree on colon cancer drug study goalshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006963&HITNO=12&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006963&THISHREF=http://c.moreover.com/click/here.pl%3fz2520943248%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006963&HITNO=12&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006963&THISHREF=http://c.moreover.com/click/here.pl%3fz2520943248%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Keryx, FDA agree on colon cancer drug study goalshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006898&HITNO=13&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006898&THISHREF=http://c.moreover.com/click/here.pl%3fz2520909602%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006898&HITNO=13&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006898&THISHREF=http://c.moreover.com/click/here.pl%3fz2520909602%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBoston Globe: Keryx, FDA Agree on Colon Cancer Drug Study Goalshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006856&HITNO=14&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006856&THISHREF=http://c.moreover.com/click/here.pl%3fz2520892922%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006856&HITNO=14&MSIZE=276&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Xeloda&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006856&THISHREF=http://c.moreover.com/click/here.pl%3fz2520892922%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNew York Times: